Director/PDMR Shareholding

Apr 29, 2019

Advanced Medical Solutions Group plc
(“AMS” or the “Group”)

RNS Number : 4643X
Advanced Medical Solutions Grp PLC
29 April 2019
 


29 April 2019

            Advanced Medical Solutions Group plc

(“AMS”, the “Company” or the “Group”)

 

            Director/PDMR Shareholding

 

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the surgical and advanced wound care specialist company, announces that the Trust which manages the Deferred Share Bonus Plan (“DSB”) on behalf of the employees of AMS has purchased ordinary shares of 5 pence each (“Ordinary Shares”) on 29 April 2019, at a price of 330p on behalf of Chris Meredith and Eddie Johnson, who are both Directors and PDMRs, as part of the DSB and, under the terms of the DSB, these shares will be held in trust on their behalf.

 

Following these transactions the beneficial ownership of Chris Meredith and Eddie Johnson are as follows:

 

Director/PDMR

Date purchased

Shares purchased

Resultant holding

% of issued share capital

Chris Meredith

Chief Executive Officer

29 April 2019

10,182

1,494,577

0.7%

Eddie Johnson

Chief Financial Officer

29 April 2019

3,847

59,426

0.028%

 

Advanced Medical Solutions Group plc further announces that it was notified on 29 April 2019 that Chris Meredith, who is a Director and PDMR, following the end of the holding period, exercised 32,638 options from the Deferred Annual Bonus Plan (DAB). Mr Meredith elected to receive an additional 369 dividend shares which were earned during the 3 year holding period under the terms of the scheme.

 

Mr Meredith subsequently sold 33,007 Ordinary Shares of 5p each on 29 April 2019 at a share price of 330p per Ordinary Share. As a result of these transactions Mr Meredith’s beneficial interest in the Company has not changed.

               

Overall Holding

 

PDMR

Holding prior to exercise (including DSB purchase)

Number of shares exercised

Dividend Shares received

Number of shares sold

Sale price (p)

Resultant holding

% of issued share capital

Chris Meredith

1,494,577

32,638

369

33,007

330p

1,494,577

0.7%

 

 

Advanced Medical Solutions Group plc also announces that on 24 April 2019, the Board, following a recommendation from the Remuneration Committee, granted new share options to the following Directors under the Advanced Medical Solutions Deferred Annual Bonus Plan (the ‘2014 DAB’).

 

This award is in respect of the part of their bonus that the Directors and PDMRs are compulsorily required to defer for the 2018 financial year. These options vest at the end of three years. Details of the current DAB holdings of the Directors/PDMRs following these awards and the exercise of DAB options by Chris Meredith are shown below:

 

Director/PDMR

Options prior to grant/exercise

Options granted

Options exercised

Resultant holding

Chris Meredith

Chief Executive Officer

77,756

12,859

32,638

57,977

Eddie Johnson

Chief Financial Officer

20,333

2,209

22,542

 

Advanced Medical Solutions Group plc further announces that on 24 April 2019, the Board, following a recommendation from the Remuneration Committee, granted new share options to the following Directors/PDMRs under the Advanced Medical Solutions Long Term Incentive Plan (the ‘LTIP’). The vesting period of these options is subject to certain performance criteria over a three year period.

 

Director/PDMR

Options prior to grant

Options granted

Resultant holding

Chris Meredith

Chief Executive Officer

476,482

182,510

 

658,992

 

Eddie Johnson

Chief Financial Officer

105,739

 

38,783

 

144,522

 

 

 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

 

 

 

 

 

1.

Details of the person discharging managerial responsibilities/person closely associated

a)

Name: Chris Meredith

2.

Reason for the notification

a)

Position/status: Director/PDMR

b)

Initial notification/Amendment: Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:   Advanced Medical Solutions Group plc

b)

LEI: 213800HJP6OWOSZI1L74

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument: Ordinary Shares of 5p

Identification code: GB0004536594

b)

Nature of the transactions:

·        Purchase of 10,182 Ordinary Shares as part of the Deferred Share Bonus Plan on 29 April 2019 at a price of 330p

c)

Price(s) and volume(s):

Sale of shares:

Price(s)

Volume(s)

n/a

n/a

d)

Aggregated information: (Relates to those shares sold only)

Aggregated volume: n/a

Aggregated price: n/a

e)

Date of the transaction: 29/04/2019

f)

Place of the transaction: London Stock Exchange, AIM Market (XLON)

 

 

 

 

 

 

 

 

 

 

 

1.

Details of the person discharging managerial responsibilities/person closely associated

a)

Name: Eddie Johnson

2.

Reason for the notification

a)

Position/status: Director/PDMR

b)

Initial notification/Amendment: Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:   Advanced Medical Solutions Group plc

b)

LEI: 213800HJP6OWOSZI1L74

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument: Ordinary Shares of 5p

Identification code: GB0004536594

b)

Nature of the transactions:

·        Purchase of 3,847 Ordinary Shares as part of the Deferred Share Bonus Plan on 29 April 2019 at a price of 330p

c)

Price(s) and volume(s):

Sale of shares:

Price(s)

Volume(s)

n/a

n/a

d)

Aggregated information: (Relates to those shares sold only)

Aggregated volume: n/a

Aggregated price: n/a

e)

Date of the transaction: 29/04/2019

f)

Place of the transaction: London Stock Exchange, AIM Market (XLON)

 

 

 

 

 

 

 

 

 

1.

Details of the person discharging managerial responsibilities/person closely associated

a)

Name: Chris Meredith

2.

Reason for the notification

a)

Position/status: Director/PDMR

b)

Initial notification/Amendment: Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:   Advanced Medical Solutions Group plc

b)

LEI: 213800HJP6OWOSZI1L74

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument: Ordinary Shares of 5p

Identification code: GB0004536594

b)

Nature of the transactions:

·        Exercise of 32,638 shares from the Deferred Annual Bonus Plan

·        Award of 369 Dividend Shares from the Deferred Annual Bonus Plan

·        Sale of 33,007 Ordinary Shares of 5p

c)

Price(s) and volume(s):

Sale of shares:

Price(s)

Volume(s)

£3.300

33,007

d)

Aggregated information: (Relates to those shares sold only)

Aggregated volume: 33,007

Aggregated price: £3.300

e)

Date of the transaction: 29/04/2019

f)

Place of the transaction: London Stock Exchange, AIM Market (XLON)

 

 

 

 

 

 

 

 

1.

Details of the person discharging managerial responsibilities/person closely associated

a)

Name: Chris Meredith

2.

Reason for the notification

a)

Position/status: Director/PDMR

b)

Initial notification/Amendment: Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:   Advanced Medical Solutions Group plc

b)

LEI: 213800HJP6OWOSZI1L74

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument: Ordinary Shares of 5p

Identification code: GB0004536594

b)

Nature of the transactions:

·        Grant of 182,510 options under the Advanced Medical Solutions Long Term Incentive Plan on 24 April 2019

·        Grant of 12,859 options under the Advanced Medical Solutions Deferred Annual Bonus Plan on 24 April 2019

c)

Price(s) and volume(s):

Sale of shares:

Price(s)

Volume(s)

n/a

n/a

d)

Aggregated information: (Relates to those shares sold only)

Aggregated volume: n/a

Aggregated price: n/a

e)

Date of the transaction: 24/04/2019

f)

Place of the transaction: London Stock Exchange, AIM Market (XLON)

 

 

 

 

 

 

 

 

 

 

1.

Details of the person discharging managerial responsibilities/person closely associated

a)

Name: Eddie Johnson

2.

Reason for the notification

a)

Position/status: Director/PDMR

b)

Initial notification/Amendment: Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:   Advanced Medical Solutions Group plc

b)

LEI: 213800HJP6OWOSZI1L74

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument: Ordinary Shares of 5p

Identification code: GB0004536594

b)

Nature of the transactions:

·        Grant of 38,783 options under the Advanced Medical Solutions Long Term Incentive Plan on 24 April 2019

·        Grant of 2,209 options under the Advanced Medical Solutions Deferred Annual Bonus Plan on 24 April 2019

c)

Price(s) and volume(s):

Sale of shares:

Price(s)

Volume(s)

n/a

n/a

d)

Aggregated information: (Relates to those shares sold only)

Aggregated volume: n/a

Aggregated price: n/a

e)

Date of the transaction: 24/04/2019

f)

Place of the transaction: London Stock Exchange, AIM Market (XLON)

 

 

-End –

 

 

 

 

 

 

 

For further information, please visit www.admedsol.com or contact:

 

Advanced Medical Solutions Group plc

Tel: 44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Mary Tavener, Chief Financial Officer




Consilium Strategic Communications

Tel: 44 (0) 20 3709 5700

Mary-Jane Elliott / Matthew Neal / Nicholas Brown / Olivia Manser

AMS@consilium-comms.com



Investec Bank PLC (NOMAD & Broker)

Tel: 44 (0) 20 7597 5970

Daniel Adams / Patrick Robb / Gary Clarence


 

About Advanced Medical Solutions Group plc see www.admedsol.com

AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical and wound care markets, focused on quality outcomes for patients and value for payors. AMS has a wide range of products that include tissue adhesives, sutures, biosurgical devices, internal sealants, silver alginates, alginates and foams, which it markets under its brands; LiquiBand®, LiquiBand® Fix 8™, RESORBA® and ActivHeal® as well as supplying under white label.

AMS‘s products, manufactured out of two sites in the UK, one in the Netherlands, two in Germany and one in the Czech Republic, are sold in more than 75 countries via a network of multinational or regional partners and distributors, as well as via AMS’s own direct sales forces in the UK, Germany, the Czech Republic and Russia.  Established in 1991, the Group has approximately 630 employees.  For more information, please see www.admedsol.com.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 

END

 
 

DSHBLGDSSDDBGCC

For further information, please contact:

Advanced Medical Solutions Group plc

Tel: 44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Eddie Johnson, Chief Financial Officer

Michael King, Investor Relations

Consilium Strategic Communications

Tel: 44 (0) 20 3709 5700

Matthew Neal / Lucy Featherstone

Investec Bank PLC (NOMAD & Broker)

Tel: 44 (0) 20 7597 5970

Gary Clarence / David Anderson

HSBC Bank PLC (Broker)

Tel: 44 (0) 20 7991 8888

Sam McLennan / Joe Weaving / Stephanie Cornish

About Advanced Medical Solutions Group plc

AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8® and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made five acquisitions: Sealantis, an Israeli developer of innovative internal sealants; Biomatlante, a French developer and manufacturer of surgical biomaterials, Raleigh, a leading UK coater and converter of woundcare and bio-diagnostics materials, AFS Medical, an Austrian specialist surgical business and Connexicon, an Irish tissue adhesives specialist.

AMS's products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, Austria, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Ireland, Germany, France and Israel. Established in 1991, the Group has more than 800 employees. For more information, please see admedsol.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.